Loading clinical trials...
Loading clinical trials...
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Cyclin-Dependent Kinase (CDK) Inhibitor SCH 727965 Administered Every 3 Weeks in Subjects With Advanced Malignancies
Conditions
Interventions
SCH 727965
SCH 727965
+5 more
Start Date
October 11, 2006
Primary Completion Date
February 22, 2010
Completion Date
February 22, 2010
Last Updated
October 23, 2017
NCT06152575
NCT06898450
NCT06179888
NCT06658951
NCT04973605
NCT05101070
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions